Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Pascual

Pulmonary Disease Hudson, FL Medical Doctor

NPI 1801896956 CMS profile 217420

7545 Medical Dr, Hudson, FL 34667

Open in the dashboard

General payments

$22,422

748 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$79,850 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Jose Pascual of Hudson, FL is reported in the CMS Open Payments database as having received $22,422 across 748 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $79,850 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,527 96
2024 General $2,277 105
2023 General $2,393 107
2022 General $2,195 79
2021 General $1,271 75
2020 General $4,946 121
2019 General $6,813 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Pascual
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jose Pascual were reported at $2,527. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jose Pascual Pulmonary Disease median Middle half National median
2019 $6,813 $377 $109–$1,340 $163
2020 $4,946 $230 $56–$907 $114
2021 $1,271 $269 $68–$1,072 $132
2022 $2,195 $390 $100–$1,457 $149
2023 $2,393 $419 $114–$1,659 $160
2024 $2,277 $476 $123–$1,818 $164
2025 $2,527 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $7,680 70 payments
  2. AstraZeneca Pharmaceuticals LP $2,234 117 payments
  3. GlaxoSmithKline, LLC. $2,211 124 payments
  4. Actelion Pharmaceuticals US, Inc. $1,787 99 payments
  5. Intuitive Surgical, Inc. $1,348 18 payments
  6. Grifols USA, LLC $674 32 payments
  7. Insmed, Inc. $666 28 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $654 27 payments
  9. United Therapeutics Corporation $551 20 payments
  10. Mallinckrodt Hospital Products Inc. $476 18 payments
  11. Other $4,140 195 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,836 733 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,690 2 payments
  3. Consulting Fee $2,808 1 payment
  4. Travel and Lodging $679 3 payments
  5. Education $409 9 payments
Products named General payments · program years 2019–2025
  1. OFEV $3,674 57 payments
  2. UPTRAVI $1,639 95 payments
  3. TRELEGY ELLIPTA $1,599 84 payments
  4. Da Vinci Surgical System $1,348 18 payments
  5. OPSUMIT $1,255 73 payments
  6. Prolastin-C Liquid $674 32 payments
  7. GLASSIA $653 27 payments
  8. TEZSPIRE $645 24 payments
  9. Arikayce $630 26 payments
  10. FASENRA $586 20 payments
  11. Other $9,158 439 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

5,383

Median for Pulmonary Disease: 936

Drug cost

$4,454,546

Median for Pulmonary Disease: $487,987

Branded share of claims

67.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opsumit Macitentan Brand 74 $920,751
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 966 $901,962
Uptravi Selexipag Brand 24 $548,267
Prolastin C Alpha-1-Proteinase Inhibitor Brand 53 $469,319
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 410 $329,661
Glassia Alpha-1-Proteinase Inhibitor Brand 13 $184,211
Adempas Riociguat Brand 11 $154,964
Ofev Nintedanib Esylate Brand 11 $144,943
Spiriva Respimat Tiotropium Bromide Brand 161 $126,940
Tezspire Tezepelumab-Ekko Brand 21 $90,437

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$263,972

Medicare's payments for the services billed

Medicare patients

892

Average age 75

Services billed

3,658

485 women, 407 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 63%
Arthritis 60%
Ischemic heart disease 59%
Chronic kidney disease 45%
Diabetes 43%
Heart failure 35%
Atrial fibrillation 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$311 21 —
TRELEGY ELLIPTA
$216 966 —
AIRSUPRA
$183 19 —
UPTRAVI
$144 24 —
OPSUMIT
$124 74 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

748 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record